The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin approved for add-on severe asthma treatment in 2021 ...

A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the health care giant says it’s ...

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...